Clinical trial
Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing…
NCT00493077 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00493077 |
|---|---|
| Title | Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy |
| Official title | A Swedish Multi-Centre, Prospective, Open Label Study: Safety of Avonex Treatment in Multiple Sclerosis Patients Who Are NAB Positive on Previous s.c Interferon Beta Therapy |
| Acronym | SAFE |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | low immunogenic interferon-beta-1a |
| Enrollment | 3 |
| Start date | May 1, 2004 |
| Primary completion | May 1, 2006 |
| Completion | May 1, 2006 |
| First posted | Jun 27, 2007 |
| Last update posted | Jan 30, 2008 |
| Countries | Sweden |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: